Aphasia Therapy: Factors of Efficacy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02804412|
Recruitment Status : Completed
First Posted : June 17, 2016
Last Update Posted : June 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Aphasia||Other: Control group Other: CIAT-group Other: communication treatment group (CTG)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Constraint Induced Aphasia Therapy in Stroke Patients in Acute Stage.|
|Study Start Date :||March 2005|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||March 2013|
Active Comparator: Control group
Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
Other: Control group
This is the control group with 14 h treatment over 10 workdays.
Patients received constraint-induced aphasia therapy.
Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
Active Comparator: communication treatment group (CTG)
Patients received aphasia group therapy without constraints
Other: communication treatment group (CTG)
Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
- Change of aphasia by Aachener Aphasia Test (AAT) [ Time Frame: pretreatment and within 24 h post intervention ]
- Change of Communication Activity Log (CAL) [ Time Frame: pretreatment and within 24 h post intervention ]The CAL is a two-part questionnaire rating the amount and the quality of daily communication on a six-point scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804412
|Principal Investigator:||Hartwig Woldag, PhD||NRZ Leipzig|